Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
about
Radioisotopes for metastatic bone painThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerTargeting bone physiology for the treatment of metastatic prostate cancerPhase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.WITHDRAWN: Radioisotopes for metastatic bone pain.Recent advances in bone-targeted therapies of metastatic prostate cancerEvolving role of bone biomarkers in castration-resistant prostate cancer.Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Castration-resistant prostate cancer: new science and therapeutic prospects.Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man studyCastration-resistant prostate cancer: systemic therapy in 2012Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastasesBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancerMultimodality therapy: bone-targeted radioisotope therapy of prostate cancerBone metastasis in prostate cancer: emerging therapeutic strategies.The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Current and emerging treatments in the management of castration-resistant prostate cancer.Radium-223 for the treatment of prostate cancer.Metabolism and pharmacokinetics of radium-223 in prostate cancer.Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer.Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.Optimal management of bone metastases in prostate cancer.
P2860
Q24235589-2B19F10B-AB88-4A60-B6D3-CE35C6B912AEQ26823733-5CFFE19E-20C3-415F-A7B6-BB7F16ACD704Q26863249-5ABFC10A-12B4-4A3F-9F74-B3137AF5703EQ33387322-FBF4ED88-F5D2-4537-97BB-CFB8152E15B5Q33396382-E02AA9D3-14A0-452D-8CB3-F13839A87514Q33405335-1DC11E91-8F91-4A50-B3B8-258B50123C91Q33408380-B6C4A8AA-2047-4B98-A76E-21F50567442BQ33440341-471875ED-9D57-4356-B93D-8BF74EDED18DQ33703763-6239312E-466F-4444-8279-B0B7140AC3EFQ34023877-9509BC03-D1DA-4B2A-83C0-47B7C7AE3331Q35057029-34D4426E-00AC-4907-AC20-6A4A0C11F47FQ35076264-F824F106-8392-4979-AFCF-746521C17906Q35592471-0C3B4351-B608-40EF-9F4A-6130DFEFAAFFQ35865011-28727BB1-6A9F-4978-A0AF-BA85AC7441FAQ36297804-56F4393D-7B74-424F-A547-B704A9C89CE4Q36840731-3AD16CA1-59D5-4D82-95EA-827DECC4821AQ37103630-2531CCB3-DD5C-48EA-9E11-14C84628D7E6Q37166534-08A2A24A-2D9B-4806-A98B-4F1BCD6BE1E5Q37168396-6EE89712-BEB0-4BE0-B3B8-DDB35955C292Q37193613-4E058E91-EE57-4B65-9DC0-1DB845AB53D4Q37873719-EA437A0A-5626-4E6B-B103-E8F9A8379AF3Q38001275-A8898769-9AAC-446F-8BEE-ADBB5B6A5B59Q38004275-3DF6F900-521C-418F-B1EB-9BE81FDF45A6Q38030595-ED3CB05A-2A19-4754-8B1B-71097692917DQ38073823-3935C619-8269-44D9-ABB9-86D402C5F4A6Q38367715-EBD94A3B-A996-413F-84B6-DB8B153BFA80Q38555581-305D0AA2-0C35-492B-9E45-0223CC47AEA7Q42140956-E623D765-38C1-4A52-BDE0-979E2E30270BQ48107105-67AEA42B-520B-4A23-B0B3-89F87FCE018EQ53266501-33DB2C02-B9BE-4E6B-9472-0AD00873DDAF
P2860
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I study of samarium-153 ...... ant metastatic prostate cancer
@en
Phase I study of samarium-153 ...... nt metastatic prostate cancer.
@nl
type
label
Phase I study of samarium-153 ...... ant metastatic prostate cancer
@en
Phase I study of samarium-153 ...... nt metastatic prostate cancer.
@nl
prefLabel
Phase I study of samarium-153 ...... ant metastatic prostate cancer
@en
Phase I study of samarium-153 ...... nt metastatic prostate cancer.
@nl
P2093
P2860
P356
P1476
Phase I study of samarium-153 ...... ant metastatic prostate cancer
@en
P2093
Anthony Delacruz
Chaitanya R Divgi
Christina Hong
Dana Rathkopf
David Solit
Glenn Heller
Gretchen A Gignac
Howard I Scher
Jorge Carrasquillo
Joseph O'Donoghue
P2860
P304
P356
10.1200/JCO.2008.20.4164
P407
P577
2009-04-13T00:00:00Z